According to TipRanks, Sutcliffe is a 3-star analyst with an average return of 2.5% and a 50.68% success rate. Sutcliffe covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, ...

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on ...

Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control ...

The business remains strong, contracts keep flowing, and yet the share price is far lower than it was a year ago. The post ...

USA-based Medicus Pharma’ Antev subsidiary has agreed to amend its licensing deal with UK-based medical research organization LifeArc relating to teverelix, an investigational next generation ...

The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as ...

Analysts think these top stocks are great options for Aussie investors. Let's see what makes them stand out. The post Top ...

Reimbursement issues, staffing shortages and rising costs are just a few of the challenges facing ASC leadership teams in 2026. Here are 20 statistics demonstrating the scale and scope of the ASC ...

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing ...

The latest announcement is out from Pro Medicus Limited ( (AU:PME) ).

Find insight on Roche Holdings, U.S. healthcare stocks and more in the latest Market Talks covering the health care sector.

Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets ...